Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors-Reference-Cited by-同舟云学术

Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors

Published:2016-03-10 Issue:10 Volume:127 Page:1269-1275
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Jain Preetesh¹²,Kantarjian Hagop¹,Patel Keyur P.³,Gonzalez Graciela Nogueras⁴,Luthra Rajyalakshmi³,Shamanna Rashmi Kanagal³,Sasaki Koji¹,Jabbour Elias¹,Romo Carlos Guillermo¹,Kadia Tapan M.¹,Pemmaraju Naveen¹,Daver Naval¹,Borthakur Gautam¹,Estrov Zeev¹,Ravandi Farhad¹,O’Brien Susan¹⁵,Cortes Jorge¹

Affiliation:

1. Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX;

2. Department of Internal Medicine, University of Texas Medical School at Houston, Houston, TX;

3. Department of Hematopathology and

4. Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX; and

5. Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, Orange, CA

Abstract

Key Points Patients with e13a2 transcripts have inferior outcomes with imatinib 400; e14a2 has favorable outcomes regardless of treatment modality. Multivariate analysis showed that the expression of e14a2 or both e14a2 and e13a2 predicts optimal ELN responses and longer EFS and TFS.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/127/10/1269/1391746/1269.pdf

Reference36 articles.

1. Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining.;Rowley;Nature,1973

2. Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22.;Groffen;Cell,1984

3. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products.;Lugo;Science,1990

4. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells.;Druker;Nat Med,1996

5. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.;Druker;N Engl J Med,2001

Cited by 125 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Establishment of genomic RNA reference materials for BCR-ABL1 P210 measurement;Analytical and Bioanalytical Chemistry;2024-09-09

2. Late presentation of chronic myeloid leukaemia patients in a low-income country: the prognostic implications and impact on treatment outcome;BMC Research Notes;2024-09-03

3. Late presentation of chronic myeloid leukaemia patients in a low-income country: The prognostic implications and impact on treatment outcome;2024-06-12

4. Variant‐specific BCR::ABL1 quantification discrepancy in chronic myeloid leukemia;International Journal of Laboratory Hematology;2024-06-05

5. Zinc as a potential regulator of the BCR-ABL oncogene in chronic myelocytic leukemia cells;Journal of Trace Elements in Medicine and Biology;2024-05